—

Organic revenue grew 16.6% annually, lifting revenue 20% to $20 b and EPS 55% to $1.95, while free cash flow margin rose seven percentage points over five years; the $14.5 b Penumbra acquisition complements highly profitable incremental sales as EPS guidance stands at $0.80 and clinical trials meet all endpoints.

Boston Scientific delivers targeted hands-on training for advanced endoscopy fellows through its sponsor-led Passport Program with covered travel and lodging, while its U.S. Electrophysiology segment faces intensifying competition, regulatory and reimbursement headwinds, despite recent FDA 510(k) clearance for the Asurys Fluid Management System and CHAMPION-AF trial success.

Investor confidence has been shaken by class-action allegations of misleading growth projections and underwhelming guidance, even as bullish narratives cite successful trial readouts, a transformative acquisition, double-digit revenue growth forecasts, and an apparently attractive valuation.

Stock experienced a sharp 17% one-day drop alongside expectations of further estimate cuts adding near-term selling pressure before a floor is established.

Revenue projected at $27.0 billion and earnings at $5.2 billion by 2029.

FDA granted clearance for the Asurys™ Fluid Management System, but a securities lawsuit and higher-than-expected stroke-risk data combine with tariff and pricing headwinds and new U.S. electrophysiology competitors, and regulator and payer responses to CHAMPION-AF WATCHMAN FLX data will determine market access.

Mixed Watchman and CHAMPION-AF results and growth concerns have driven near-term selling and downgrades, while narratives of robust trial success and deep valuation discounts foster cautious optimism about long-term upside.